Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) and GelStat (OTCMKTS:GSAC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Aldeyra Therapeutics and GelStat”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aldeyra Therapeutics | N/A | N/A | -$33.85 million | ($0.46) | -3.70 |
| GelStat | N/A | N/A | N/A | N/A | N/A |
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Aldeyra Therapeutics | N/A | -57.34% | -36.33% |
| GelStat | N/A | N/A | N/A |
Institutional and Insider Ownership
59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 9.6% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 20.5% of GelStat shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Aldeyra Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, GelStat has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Aldeyra Therapeutics and GelStat, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aldeyra Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
| GelStat | 0 | 0 | 0 | 0 | 0.00 |
Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 223.53%. Given Aldeyra Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Aldeyra Therapeutics is more favorable than GelStat.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
About GelStat
GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
